Acute hepatitis B notification rates in Flanders, Belgium, 2009 to 2017.

Özgür Koc, Pierre Van Damme, Dana Busschots, Rob Bielen, Anmarie Forier, Frederik Nevens, Geert Robaeys

Journal: Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin 2020;24(30):1900064

PMID: 31362809

Abstract

BackgroundBelgium is a low-endemic country for hepatitis B. Universal hepatitis B vaccination in infants with catch-up in the age cohort of 10-13 year-olds began in 1999.AimsOur objective was to evaluate the effect of prevention and control strategies on acute hepatitis B notification rates in Flanders (Belgium) from 2009 to 2017.MethodsThis observational study collected demographic data and risk factors for acute hepatitis B from mandatory notifications to the Agency for Care and Health.ResultsIn Flanders, acute hepatitis B notification rates per 100,000 population decreased from 1.6 in 2009 to 0.7 in 2017. These rates declined in all age groups: 0-4-year-olds: 0.6 to 0.0, 5-14-year-olds: 0.2 to 0.0, 15-24-year-olds: 0.8 to 0.7, 25-34-year-olds: 3.4 to 1.1 and ≥ 35-year-olds: 1.59 to 0.7. There was also a downward trend in acute hepatitis B notification rates in native Belgians and first-generation migrants. Among 15-24-year-olds and 25-34-year-olds, a possible reversal of the decreasing trend was observed in 2016 and 2015, respectively. Among 548 acute hepatitis B cases, the main route of transmission was sexual activity (30.7%), and the pattern of transmission routes over time showed an increasing proportion of sexual transmission in men who have sex with men (MSM) after 2014. During the period from 2009 to 2017, five mother-to-child transmissions were reported.ConclusionsPrevention and control strategies were effective in reducing the acute hepatitis B notification rate. However, stronger prevention and control measures are needed in adult risk groups, particularly MSM.

Address: Department of Gastroenterology and Hepatology, Ziekenhuis Oost-Limburg, Genk, Belgium.; Faculty of Medicine and Life Sciences, Hasselt University, Hasselt, Belgium.; Department of Medical Microbiology, School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Centre, Maastricht, the Netherlands.; Vaccine and Infectious Disease Institute, Centre for the Evaluation of Vaccination, Antwerp University, Wilrijk, Belgium.; Department of Gastroenterology and Hepatology, Ziekenhuis Oost-Limburg, Genk, Belgium.; Faculty of Medicine and Life Sciences, Hasselt University, Hasselt, Belgium.; Department of Infectious Disease Control, Agency for Care and Health, Limburg, Belgium.; Department of Gastroenterology and Hepatology, University Hospitals KULeuven, Leuven, Belgium.; Department of Gastroenterology and Hepatology, Ziekenhuis Oost-Limburg, Genk, Belgium.; Faculty of Medicine and Life Sciences, Hasselt University, Hasselt, Belgium.; Department of Gastroenterology and Hepatology, University Hospitals KULeuven, Leuven, Belgium.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.